受试者n |
50 |
27 |
304 |
|
年龄 |
53.48±19.92 |
50.56±13.38 |
54.78±9.82 |
0.138 |
女性 |
27(54.00) |
10(37.04) |
141(46.38) |
0.353 |
种族 |
|
|
|
|
Caucasian |
44(88.00) |
20(74.07) |
238(78.29) |
0.231 |
African American |
6(12.00) |
7(25.93) |
66(21.71) |
|
吸烟状况 |
|
|
|
|
Ever/current |
4(8.00) |
12(44.44) |
99(32.56) |
0.001 |
Never |
46(92.00) |
15(55.55) |
205(67.43) |
|
机构 |
|
|
|
|
National Jewish Health |
|
|
75(24.67) |
|
University of California-San Francisco |
|
|
55(18.09) |
|
Johns Hopkins University |
|
|
44(14.47) |
|
University of Pennsylvania |
|
|
43(14.14) |
|
Vanderbilt University |
|
|
34(11.18) |
|
University of Pittsburgh |
|
|
26(8.55) |
|
Arizona Health Science Center |
|
|
24(7.87) |
|
Medical University of South Carolina |
|
|
3(0.01) |
|
疾病持续时间 |
|
5.93±8.08 |
11.92±18.03 |
0.001 |
肺外疾病 |
|
20(74.07) |
214(70.39) |
0.827 |
刺伤阶段 |
|
|
|
|
Stage 0 |
|
6(22.22) |
34(11.18) |
0.116 |
Stage I |
|
4(14.81) |
67(22.04) |
0.471 |
Stage II |
|
12(44.44) |
90(29.61) |
0.129 |
Stage III |
|
0(0.00) |
41(13.49) |
0.034 |
Stage IV |
|
5(18.52) |
72(23.68) |
0.641 |
FVC%pred |
|
89.67±16.48 |
87.18±16.27 |
0.476 |
FEV1%pred |
|
87.37±20.77 |
83.88±20.64 |
0.485 |
FEV1/fvc |
|
0.78±0.04 |
0.75±0.15 |
0.379 |
dLCO%pred |
|
75.30±16.67 |
81.35±23.49 |
0.181 |
免疫抑制剂治疗 |
|
13(48.15) |
267(87.83) |
<0.0001 |